Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.51
NYSE:BCR's Cash-to-Debt is ranked lower than
67% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. NYSE:BCR: 0.51 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:BCR' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.62 Max: N/A
Current: 0.51
Equity-to-Asset 0.32
NYSE:BCR's Equity-to-Asset is ranked lower than
83% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. NYSE:BCR: 0.32 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:BCR' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.28  Med: 0.54 Max: 0.77
Current: 0.32
0.28
0.77
Interest Coverage 16.51
NYSE:BCR's Interest Coverage is ranked lower than
63% of the 139 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 47.64 vs. NYSE:BCR: 16.51 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BCR' s Interest Coverage Range Over the Past 10 Years
Min: 15.05  Med: 23.74 Max: 60.49
Current: 16.51
15.05
60.49
Piotroski F-Score: 8
Altman Z-Score: 5.09
Beneish M-Score: -2.40
WACC vs ROIC
4.06%
32.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 25.47
NYSE:BCR's Operating Margin % is ranked higher than
90% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.03 vs. NYSE:BCR: 25.47 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:BCR' s Operating Margin % Range Over the Past 10 Years
Min: 18.91  Med: 25.4 Max: 39.79
Current: 25.47
18.91
39.79
Net Margin % 15.70
NYSE:BCR's Net Margin % is ranked higher than
81% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.21 vs. NYSE:BCR: 15.70 )
Ranked among companies with meaningful Net Margin % only.
NYSE:BCR' s Net Margin % Range Over the Past 10 Years
Min: 3.96  Med: 17.46 Max: 22.62
Current: 15.7
3.96
22.62
ROE % 36.19
NYSE:BCR's ROE % is ranked higher than
96% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.23 vs. NYSE:BCR: 36.19 )
Ranked among companies with meaningful ROE % only.
NYSE:BCR' s ROE % Range Over the Past 10 Years
Min: 8.19  Med: 22.49 Max: 36.19
Current: 36.19
8.19
36.19
ROA % 11.28
NYSE:BCR's ROA % is ranked higher than
83% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. NYSE:BCR: 11.28 )
Ranked among companies with meaningful ROA % only.
NYSE:BCR' s ROA % Range Over the Past 10 Years
Min: 2.73  Med: 14.07 Max: 17.1
Current: 11.28
2.73
17.1
ROC (Joel Greenblatt) % 86.69
NYSE:BCR's ROC (Joel Greenblatt) % is ranked higher than
91% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.30 vs. NYSE:BCR: 86.69 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:BCR' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 53.37  Med: 81.73 Max: 148.85
Current: 86.69
53.37
148.85
3-Year Revenue Growth Rate 9.30
NYSE:BCR's 3-Year Revenue Growth Rate is ranked higher than
69% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. NYSE:BCR: 9.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:BCR' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -0.7  Med: 9.1 Max: 13.9
Current: 9.3
-0.7
13.9
3-Year EBITDA Growth Rate -10.70
NYSE:BCR's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. NYSE:BCR: -10.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:BCR' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -18.9  Med: 8.6 Max: 41.1
Current: -10.7
-18.9
41.1
3-Year EPS without NRI Growth Rate -5.70
NYSE:BCR's 3-Year EPS without NRI Growth Rate is ranked lower than
60% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. NYSE:BCR: -5.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:BCR' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -34  Med: 10.1 Max: 43.4
Current: -5.7
-34
43.4
GuruFocus has detected 5 Warning Signs with C.R. Bard Inc $NYSE:BCR.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:BCR's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ILMN, OTCPK:CLPBY, OTCPK:ESLOY, NYSE:MTD, NYSE:WAT, OTCPK:TRUMF, NAS:XRAY, NAS:HOLX, NYSE:BAX, OTCPK:OCPNY, NYSE:COO, NYSE:RMD, OTCPK:SAUHY, NYSE:WST, NYSE:STE, NYSE:HRC, OTCPK:GNGBF, NAS:ICUI, NYSE:CMD, NAS:PODD » details
Traded in other countries:BR6.Germany,
Headquarter Location:USA
C.R. Bard Inc manufactures, distributes and sells medical, surgical, diagnostic and patient care devices. The Company sells its products to hospitals, individual healthcare professionals, and extended care facilities.

C.R. Bard designs, manufactures, and markets a wide range of medical, diagnostic, and surgical devices that are primarily intended for one-time use. The firm enjoys a sizable footprint in key therapeutic areas, including urology, oncology, peripheral vascular solutions, soft tissue surgery, and breast biopsy and reconstruction. Sales to foreign countries account for approximately one third of total revenue.

Guru Investment Theses on C.R. Bard Inc

Donald Yacktman Comments on C.R. Bard - Nov 05, 2015

C.R. Bard (NYSE:BCR) was a solid performer in the third quarter. As a result, we reduced the Fund’s position size in Bard.

From Donald Yacktman (Trades, Portfolio)'s third quarter 2015 commentary.

Check out Donald Yacktman latest stock trades

Top Ranked Articles about C.R. Bard Inc

BD and Bard Receive Second Requests from FTC under HSR Act
Lifshitz & Miller LLP Announces Investigation of C. R. Bard, Inc., HCSB Financial Corp., Home Capital Group Inc., Paragon Commercial Corporation, PCM, Inc., Pingtan Marine Enterprise Ltd. and United States Steel Corporation
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of C. R. Bard, Inc. to Becton, Dickinson and Company for $317 Per Share is Fair to Shareholders - BCR
WeissLaw LLP: The C. R. Bard, Inc. and Becton, Dickson and Company Merger May Not Be in the Best Interests of BCR Unitholders
C.R. BARD INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of C.R. Bard, Inc.
Harwood Feffer LLP Announces Investigation of C. R. Bard, Inc.
Act Now - Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of C.R. Bard, Inc. - BCR
BD Announces Appointment Of Tom Polen As President
BD To Acquire Bard For $24 Billion
Tom Gayner Sells 5 Holdings, Reduces 1 Other An overview of the guru's 3rd quarter sales
Tom Gayner (Trades, Portfolio) is co-CEO of Markel Corp., and president and chief investment officer of Markel-Gayner Asset Management. During the third quarter, the guru reduced or exited the following holdings: Read more...

Ratios

vs
industry
vs
history
PE Ratio 40.21
BCR's PE Ratio is ranked lower than
70% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. BCR: 40.21 )
Ranked among companies with meaningful PE Ratio only.
BCR' s PE Ratio Range Over the Past 10 Years
Min: 14.25  Med: 24.55 Max: 154.75
Current: 40.21
14.25
154.75
Forward PE Ratio 27.17
BCR's Forward PE Ratio is ranked higher than
56% of the 39 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.62 vs. BCR: 27.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 40.21
BCR's PE Ratio without NRI is ranked lower than
70% of the 125 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.49 vs. BCR: 40.21 )
Ranked among companies with meaningful PE Ratio without NRI only.
BCR' s PE Ratio without NRI Range Over the Past 10 Years
Min: 14.25  Med: 24.38 Max: 154.75
Current: 40.21
14.25
154.75
Price-to-Owner-Earnings 98.61
BCR's Price-to-Owner-Earnings is ranked lower than
86% of the 84 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 33.25 vs. BCR: 98.61 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BCR' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.25  Med: 25.02 Max: 434.61
Current: 98.61
12.25
434.61
PB Ratio 13.68
BCR's PB Ratio is ranked lower than
96% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.28 vs. BCR: 13.68 )
Ranked among companies with meaningful PB Ratio only.
BCR' s PB Ratio Range Over the Past 10 Years
Min: 3.22  Med: 4.79 Max: 13.69
Current: 13.68
3.22
13.69
PS Ratio 6.29
BCR's PS Ratio is ranked lower than
74% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.25 vs. BCR: 6.29 )
Ranked among companies with meaningful PS Ratio only.
BCR' s PS Ratio Range Over the Past 10 Years
Min: 2.55  Med: 3.64 Max: 6.29
Current: 6.29
2.55
6.29
Price-to-Free-Cash-Flow 45.96
BCR's Price-to-Free-Cash-Flow is ranked lower than
72% of the 71 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.86 vs. BCR: 45.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BCR' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.99  Med: 17.61 Max: 49.94
Current: 45.96
9.99
49.94
Price-to-Operating-Cash-Flow 38.30
BCR's Price-to-Operating-Cash-Flow is ranked lower than
76% of the 93 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.73 vs. BCR: 38.30 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BCR' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 8.99  Med: 14.99 Max: 40.5
Current: 38.3
8.99
40.5
EV-to-EBIT 30.45
BCR's EV-to-EBIT is ranked lower than
67% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.50 vs. BCR: 30.45 )
Ranked among companies with meaningful EV-to-EBIT only.
BCR' s EV-to-EBIT Range Over the Past 10 Years
Min: 8  Med: 15.9 Max: 49.4
Current: 30.45
8
49.4
EV-to-EBITDA 23.95
BCR's EV-to-EBITDA is ranked lower than
69% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.46 vs. BCR: 23.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
BCR' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.2  Med: 13.4 Max: 31.5
Current: 23.95
7.2
31.5
PEG Ratio 17.48
BCR's PEG Ratio is ranked lower than
98% of the 66 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. BCR: 17.48 )
Ranked among companies with meaningful PEG Ratio only.
BCR' s PEG Ratio Range Over the Past 10 Years
Min: 0.92  Med: 1.64 Max: 40.4
Current: 17.48
0.92
40.4
Shiller PE Ratio 58.85
BCR's Shiller PE Ratio is ranked lower than
57% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.38 vs. BCR: 58.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
BCR' s Shiller PE Ratio Range Over the Past 10 Years
Min: 23.35  Med: 31.81 Max: 58.87
Current: 58.85
23.35
58.87
Current Ratio 1.48
BCR's Current Ratio is ranked lower than
76% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. BCR: 1.48 )
Ranked among companies with meaningful Current Ratio only.
BCR' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 2.22 Max: 5.88
Current: 1.48
1.14
5.88
Quick Ratio 1.16
BCR's Quick Ratio is ranked lower than
71% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. BCR: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
BCR' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.66 Max: 4.72
Current: 1.16
0.62
4.72
Days Inventory 123.52
BCR's Days Inventory is ranked higher than
53% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.19 vs. BCR: 123.52 )
Ranked among companies with meaningful Days Inventory only.
BCR' s Days Inventory Range Over the Past 10 Years
Min: 99.01  Med: 105.62 Max: 123.52
Current: 123.52
99.01
123.52
Days Sales Outstanding 43.46
BCR's Days Sales Outstanding is ranked higher than
78% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. BCR: 43.46 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 43.46  Med: 59 Max: 63.66
Current: 43.46
43.46
63.66
Days Payable 26.49
BCR's Days Payable is ranked lower than
86% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.69 vs. BCR: 26.49 )
Ranked among companies with meaningful Days Payable only.
BCR' s Days Payable Range Over the Past 10 Years
Min: 18.23  Med: 20.88 Max: 28.74
Current: 26.49
18.23
28.74

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.33
BCR's Dividend Yield % is ranked lower than
92% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. BCR: 0.33 )
Ranked among companies with meaningful Dividend Yield % only.
BCR' s Dividend Yield % Range Over the Past 10 Years
Min: 0.32  Med: 0.68 Max: 0.9
Current: 0.33
0.32
0.9
Dividend Payout Ratio 0.13
BCR's Dividend Payout Ratio is ranked higher than
84% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BCR: 0.13 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BCR' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.1  Med: 0.15 Max: 0.52
Current: 0.13
0.1
0.52
3-Year Dividend Growth Rate 6.80
BCR's 3-Year Dividend Growth Rate is ranked lower than
59% of the 64 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. BCR: 6.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BCR' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 3.2  Med: 6.3 Max: 24.1
Current: 6.8
3.2
24.1
Forward Dividend Yield % 0.33
BCR's Forward Dividend Yield % is ranked lower than
93% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.27 vs. BCR: 0.33 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.44
BCR's 5-Year Yield-on-Cost % is ranked lower than
84% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BCR: 0.44 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BCR' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.43  Med: 0.91 Max: 1.2
Current: 0.44
0.43
1.2
3-Year Average Share Buyback Ratio 2.00
BCR's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 131 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.20 vs. BCR: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -3  Med: 1.6 Max: 5.3
Current: 2
-3
5.3

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.88
BCR's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
64% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.24 vs. BCR: 2.88 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BCR' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.89  Med: 1.58 Max: 2.89
Current: 2.88
0.89
2.89
Price-to-Intrinsic-Value-DCF (Earnings Based) 3.76
BCR's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
77% of the 22 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.12 vs. BCR: 3.76 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.73
BCR's Price-to-Median-PS-Value is ranked lower than
79% of the 174 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. BCR: 1.73 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCR' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.26  Med: 0.71 Max: 1.73
Current: 1.73
0.26
1.73
Earnings Yield (Greenblatt) % 3.29
BCR's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.66 vs. BCR: 3.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCR' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 6.3 Max: 12.5
Current: 3.29
2
12.5
Forward Rate of Return (Yacktman) % 4.50
BCR's Forward Rate of Return (Yacktman) % is ranked lower than
67% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.07 vs. BCR: 4.50 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BCR' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.5  Med: 17.4 Max: 22.9
Current: 4.5
4.5
22.9

More Statistics

Revenue (TTM) (Mil) $3,779.30
EPS (TTM) $ 7.86
Beta0.34
Short Percentage of Float0.97%
52-Week Range $203.63 - 316.80
Shares Outstanding (Mil)72.44

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 3,944 4,204
EPS ($) 11.62 12.51 13.96
EPS without NRI ($) 11.62 12.51 13.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.19%
Dividends per Share ($) 0.99 0.99
» More Articles for BCR

Headlines

Articles On GuruFocus.com
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 
Stocks That Fell to 3-Year Lows in the Week of June 23 Jun 24 2017 
Weekly Top Insider Buys Highlight for the Week of June 23 Jun 24 2017 
ID Watchdog Announces Special and Annual General Meeting Date and Record Date Jun 23 2017 
Ironclad Performance Wear Postpones 2017 Annual Meeting of Stockholders Jun 23 2017 
Delta and Korean Air Create Leading trans-Pacific Joint Venture Jun 23 2017 
Harwood Feffer LLP Announces Investigation of EnerNOC, Inc. Jun 23 2017 

More From Other Websites
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against C. R. Bard, Inc. Jun 22 2017
Bard Declares Quarterly Dividend Jun 14 2017
Seven iQ100 members hit all-time highs Jun 14 2017
BD and Bard Receive Second Requests from FTC under HSR Act Jun 09 2017
Four members of iQ100 hitting all-time highs Jun 09 2017
Nine members of iQ100 hit all time highs Jun 01 2017
Albany public company files lawsuit alleging competitor violated antitrust laws May 31 2017
ETFs with exposure to C.R. Bard, Inc. (New Jersey) : May 31, 2017 May 31 2017
C.R. Bard (BCR) Up 1.6% Since Earnings Report: Can It Continue? May 23 2017
Becton, Dickinson and Company -- Moody's assigns Baa2 to Becton Dickinson's new euro senior... May 23 2017
Lifshitz & Miller LLP Announces Investigation of C. R. Bard, Inc., HCSB Financial Corp., Home... May 15 2017
CR Bard (BCR) Hits a 52-Week High: What's Driving the Stock? May 15 2017
Becton, Dickinson and Company -- Moody's Assigns Ba1 to Becton Dickinson's Exchange Notes May 09 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of... May 02 2017
C.R. Bard, Inc. (New Jersey) :BCR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 May 01 2017
INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of C.R. Bard, Inc.... Apr 30 2017
Five CNBC IQ 100 components are hitting lifetime highs Apr 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}